Clinical Trial Update: A Safety Study of Intravenous Pro-Netupitant and Palonosetron Combination for the Prevention of Nausea and Vomiting [Phase 3]

View source ↗

Summary

Complete Phase 3 safety study evaluating intravenous netupitant (Pro-Netupitant) in combination with palonosetron for prevention of chemotherapy-induced nausea …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chemotherapy-induced Nausea and Vomiting

Drugs mentioned

• Palonosetron (palonosetron)
• Pro-Netupitant (netupitant)

Snippet

Sponsor: Helsinn Healthcare SA | Conditions: Chemotherapy-Induced Nausea and Vomiting | Phase 3 | Status: COMPLETED | Results posted: 2018-06-20